SR One

Simeon is CEO and Managing Partner of SR One. Simeon co-founded SR One following its spin-out from GSK in 2020. Previously, he worked in management consulting (Bain & Co.) and investment banking (Goldman Sachs). Simeon led SR One’s investments in several marquee deals including CRISPR Therapeutics (CRSP), Principia Biopharma (PRNB), Turning Point Therapeutics (TPTX), Progyny (PGNY), and he co-founded both Nkarta Therapeutics (NKTX) and Arcellx (ACLX).

Simeon has a B.A. from the Johns Hopkins University and an M.D./M.B.A. from the University of Pennsylvania School of Medicine/The Wharton School.